The prolactin response to fenfluramine in schizophrenia is associated with negative symptoms

Schizophrenia Research

Volumn 39, Issue 1, 1999, Pages 85-89

  Sharma, Rajiv P ^a   Singh, Vivek ^b   Janicak, Philip G ^a   Javaid, Javaid I ^a   Pandey, Ghanshyam N ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cortisol; Fenfluramine; Negative symptoms; Prolactin; Schizoaffectve disorders; Schizophrenia

Indexed keywords

FENFLURAMINE; HYDROCORTISONE; PLACEBO; PROLACTIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; MALE; NEGATIVE SYNDROME; NEUROENDOCRINOLOGY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; SCHIZOIDISM; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM;

ADMINISTRATION, ORAL; ADULT; BRIEF PSYCHIATRIC RATING SCALE; FEMALE; FENFLURAMINE; HUMANS; HYDROCORTISONE; MALE; PROLACTIN; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 0033370091     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(99)00014-6     Document Type: Article

References (23)

1. Abel K.M., O'Keane V., Murray R.M. Enhancement of the prolactin response to d-fenfluramine in drug-naïve schizophrenic patients. Biol. Psychiatry. 168:1996;57-60.
2. Bleich A., Brown S.L., Kahn R., et al. The role of serotonin in schizophrenia. Schizophr. Bull. 14:1988;297-315.
3. Brier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr. Res. 14:1995;187-202.
4. Chase T.N., Shoulson I. Behavioral and biochemical effects of fenfluramine in patients with neurologic disease. Postgrad. Med. J. 51:(Suppl. 1):1975;105-109.
5. Csernansky J.G., King R.J., Faustman W.O., Moses J.A., Poscher M.E., Faull K.F. 5-HIAA in cerebrospinal fluid and deficit schizophrenic characlearistia. Brit. J. Psychiat. 156:1990;501-507.
6. Curtis V.A., Wright P., Reveley A., Kerwin R., Lucey J.V. Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. Br. J. Psychiatry. 166:1995;642-646.
7. Coccaro E.C., Kavoussi R.J., Cooper T.B., Hauger R.L. Hormonal responses to d- and d,l-fenfluramine in healthy human subjects. Neuropsychopharmacology. 15:(6):1996;595-607.
8. Coccaro E.C., Kavoussi R.J., Cooper T.B., Hauger R. 5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response to d-fenfluramine challenge in healthy subjects. Psychopharmacology. 127:1996;108-112.
9. Dinan T.G. Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. Life Sci. 58:1996;1683-1694.
10. Feeney S., Goodall E., Silverstone T. The prolactin response to d- and l-fenfluramine and to d-amphetamine in human subjects. Int. Clin. Psychopharmacol. 8:1993;49-54.
11. Gibson E.L., Kennedy A.J., Curzon G. d-Fenfluramine and d-norfenfluramine-induced hypophagia: differential mechanism and involvement of postsynaptic 5-HT receptors. Eur. J. Pharmacol. 242:1993;83-90.
12. Goodal E.M., Cowen P.J., Franklin M., Silverstone T. Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacology. 112:1993;461-466.
13. Invernizzi R., Berettera C., Consolo S., Garattini S., Sumanin R. d- and l- isomers of fenfluramine differ markedly in their interaction with brain serotonin and cathecolamine in the rat. Eur. J. Pharmacol. 120:1986;9-15.
14. Invernizzi R., Bertorelli R., Consolo S., Garattini S., Sumanin R. Effects of the l isomer of fenfluramine on dopamine mechanism in rat brains:further studies. Eur. J. Pharmacol. 164:1989;241-248.
15. Lemus C.Z., Lieberman J.A., Johns C.A., Mayerhoff D.I., Pollack S., Cooper T.B., Novacenko H. Hormonal response to fenfluramine challenges in clozapine-treated schizophrenic patients. Biol. Psychiatry. 29:1991;691-694.
16. McCann U.D., Hatzidimitriou G., Ricaurte G.A. Prolactin response to fenfluramine is independent of serotonin release. Eur. J. Pharmacol. 312:1996;R1-R2.
17. Meltzer H.Y., Maes M. Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man. Psychopharmacology. 114:1994;635-643.
18. Park S.B.G., Cowen P.J. Effect of pindolol on the prolactin response to d-fenfluramine. Psychopharmacology. 118:1995;471-474.
19. Quattrone A., Tedeschi G., Aguglia U., Scopacasa F., Direnzo G.F., Annunziato L. Prolactin secretion in man: a useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurones. Studies with fenfluramine. Br. J. Clin. Pharmacol. 16:1983;471-475.
20. Rittenhouse P.A., Levvy A.D., Li Q., Bethea C.L., Van D.E., Kar L.D. Neurons in the hypothalamic paraventricular nucleus mediate the serotonergic stimulation of prolactin secretion via 5-HT1c/2 receptors. Endocrinology. 133:1993;661-667.
21. Sharma R.P., Shapiro L. 5ht1a systems in schizophrenia: implications for pathophysiology and treatment. Psychiatr. Ann. 26:(2):1996;88-92.
22. Sharma R.P., Kamath S., Shapiro L., Soll E., Watanabe M., Davis J.M. Acute dietary tryptophan depletion: effects on schizophrenic positive and negative symptoms. Neuropsychobiology. 35:1997;5-10.
23. Stoff D.M., Pasatiempo A.P., Yeung J.H., Bridger W.H., Rabinovich H. Test-retest reliability of the prolactin and cortisol responses to d,l-fenfluramine challenge in disruptive behavior disorders. Psychiatry Res. 42:1992;65-72.